It’s time for an update on TLRs – Toll-like receptors – as a way of igniting the fire of the tumour microenvironment. We have repeatedly seen how only a minority of patients respond to immune checkpoint blockade and how there are a multitude of reasons for why this is the case.
In some patients, the immune response is stalled in some way, thereby necessitating a jumpstart. Reasons for this might include lack of recognition of the cancer cells, poor antigen presentation, immunosuppression, immune escape and so on.
In other words, we need more firepower and novel rational combination approaches to stimulating both the innate and the adaptive immune systems in order to derive a more potent and durable response in a larger number of patients. That’s where TLR agonists come in.
As always in oncology R&D, there have been some failures already but we have also seen more promising compounds emerge as well as improved understanding of the science behind the immune system defects that occur in cancer.
Armed with this knowledge, will the current crop of molecules produce better results? To find out, we took at look at some of the recently available data and also interviewed an emerging new company in this niche to learn more about their quite different approach to the challenges…
To learn more from our latest thought leader interviews and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
This is the third in our mini-series previewing the forthcoming European Society for Medical Oncology 2016 Congress in Copenhagen (Twitter #ESMO16).
In this post we’re taking a look at what’s hot in head and neck cancer.
It’s not a cancer type we typically hear a lot about, but there’s an unmet medical need for effective new treatments.
To learn more about our insights on this intriguing topic, subscribers can log-in…
One of the (many) highlights for me at the recent annual meeting of the American Association for Cancer Research (AACR) was a “Meet the Expert” session presented by Professor George Coukos.
Prof George Coukos AACR 2016
Professor Coukos is Director of Oncology at the University Hospital of Lausanne and Director of the Ludwig Institute for Cancer Research in Switzerland.
Ovarian cancer is becoming a fascinating battleground for cancer immunotherapy, with multiple challenges that must be overcome before we see improvements in outcomes, especially for women advanced disease.
The interview with Prof Coukos is a follow-on to the one we did on advanced ovarian cancer and checkpoint blockade at ECCO 2015 in Vienna with Dr Nora Disis (Link).
If you missed it, you can still listen to highlights in Episode 7 of the Novel Targets Podcast (Link).
After his AACR presentation, Prof Coukos kindly spoke with BSB and in a wide ranging discussion, highlighted some of the innovative clinical trial strategies he is working on to move the cancer immunotherapy field forward in ovarian cancer.
Subscribers can login to learn more about this important topic or you can purchase access.